Systemic Therapy of HER2-positive Breast Cancer
|
|
- Eustacia Wade
- 5 years ago
- Views:
Transcription
1 Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018
2 HER2-positive Breast Cancer Adjuvant trastuzumab trials: Relative risk reduction of death HER2-directed therapy in ABC: Survival rates Relative Risk Risk od death 33-59% Analysis Year Expected: 5-year Survival (%) Expected: Mean Per-Patient Survival (Months) Roth J, et al. ESMO Courtesy of M. Piccart HER2-directed therapy is the largest achievements in medical treatment of breast cancer, during the last decade! HER2 is a molecular driver of approx. 20% of BC. EBC: Uniform efficacy, % improvement in DFS and OS. MBC: Doubling of overall survival time.
3 Adjuvant HER2-directed Therapy
4 Adjuvant Trastuzumab: Pivotal Phase 3 Trials Trial HERA Piccart-Gebhart M, et al. NEJM 2015 Cameron D, et al. Lancet NCCTG N9831 and NSABP-B31 Perez EA, et al. J Clin Oncol BCIRG 006 Slamon DJ, et al. SABCS FNCLCC-PACS 04 Spielmann M, et al. J Clin Oncol Study Design Phase 3 Phase 3 Phase 3 Phase 3 No. of Patients Treatment Arm DFS Absolute values HR (95% CI; p) OS Absolute values HR (95% CI; p) 1,698 Observation 11-year DFS: 63.0% 12-year OS: 72.9% 1,703 Sequential trastuzumab 1 yr 11-year DFS: 69.3% 0.76 ( ; <0.0001) 12-year OS: 79.4% 0.74 ( ; <0.0001) 1,701 Sequential trastuzumab 2 yrs 11-year DFS: 68.5% 0.77 ( ; <0.0001) 12-year OS: 79.5% 0.72 ( ; <0.0001) 2,018 CT 8-year DFS: 62.0% 8-year OS: 75.2% 2,028 CT + 8-year DFS: 73.7% 8-year OS: 84.0% trastuzumab 1 yr 0.60 ( ; < ( ; <0.001) 1,073 AC -> T 10-year DFS: 67.9% 10-year OS: 78.7% 1,074 AC -> TH -> trastuzumab 1 yr 10-year DFS: 74.6% 0.72 ( ; <0.0001) 10-year OS: 85.9% 0.63 ( ; <0.0001) 1,075 TCH -> trastuzumab 1 yr 10-year DFS: 73.0% 0.77 ( ; ) 10-year OS: 83.3% 0.76 ( ; ) 260 Observation 3-year DFS: 77.9% 3-year OS: 96.0% 268 Sequential trastuzumab 1 yr 3-year DFS: 80.9% 0.86 ( ; 0.41) 3-year OS: 95.0% 1.27 ( ; NS)
5 Trastuzumab is Effective Regardless Nodal and/or HR Status: HERA Trial Subgroup (no. patients) HR (95% CI) Nodal status Not assessed (neoadjuvant chemotherapy) (372) 0.66 (0.43, 1.00) Negative (1099) 0.59 (0.39, 0.91) 1 3 positive nodes (976) 0.61 (0.43, 0.87) 4 positive nodes (953) 0.64 (0.49, 0.83) Hormone receptor status ER negative + PgR negative (1627) 0.63 (0.50, 0.78) ER negative + PgR positive (172) 0.77 (0.34, 1.74) ER positive + PgR negative (460) 0.82 (0.50, 1.34) ER positive + PgR positive (984) 0.63 (0.43, 0.93) All patients (3401) 0.64 (0.54, 0.76) Favours trastuzumab HR Favours observation Untch, et al. Ann Oncol 2008.
6 Concurrent Trastuzumab Performs Better than Sequential: NCCTG N9831Trial Perez, et al. Cancer Res 2009.
7 Benefit of Trastuzumab in Small 2cm N0 Disease: Meta-Analysis HR + HR - Only smal number (n=75) pts with T1a/b ( 1 cm) included! O Sullivan C, et al. J Clin Oncol 2015 Trastuzumab is recommended for patients with T1c (> 1cm) tumors, while its role in tumors 1 cm is still debatable.
8 No Benefit of Trastuzumab in HER2-low Disease: NSABP B-47 Trial (HER2 IHC 1+/2+ and ISH-negative) Fehrenbacher L, et al. SBCS There is no benefit of adjuvant trastuzumab in HER2-negative disease.
9 Cardiac Safety of 1 year Adjuvant HER2-directed Therapy Trial Arm Any CHF (%) Any LVEF drop (%) HERA, de Azambuja, et al. (2014) Chemo Chemo T 1y NSABP B-31, Romond, et al. (2012) AC P 1.2 NR AC PT NCCTG N9831, Advani, et al. (2016) AC P AC P T AC PT BCIRG 006, Slamon, et al. (2015) AC D AC DT DCarboT APT, Tolaney, et al. (2015) PT ALLTO, Piccart M, et al. (2016) APHINITY, von Von Minckwitz, et al. (2017) Chemo T 1y Chemo T Lapa 1y Chemo T + Lapa 1y Chemo T 1y Chemo T + Pertuz 1y < Risk factors for CHF: low LVEF, age, obesity, hypertension. LVEF is mandatory before initiation of trastuzumab and during treatment
10 Escalation and De-escalation of Adjuvant Anti-HER2 Therapy Adjuvant treatment if no pcr KATHERINE: T-DM1 (on-going) Escalating targeted agents BETH: H + Bevacizumab (negative) ExteNET: H -> neratinib (positive) ALTTO: H -> L or H+L (negative) APHINITY: H + pertuzumab (positive) KAITLIN: T-DM1 + pertuzumab (on-going) Prolonging duration of adjuvant H HERA: H for 2 years (negative) ANTHRACYCLINE AND TAXANE BASED CHEMOTHERAPY WITH TRASTUZUMAB FOR ONE YEAR Non-anthracycline-based CT BCIRG 006: TCH regimen (positive) APT: weekly P + H (positive) CT-free regimen ATEMPT: T-DM1 (on-going) Reducing duration of adjuvant H PHARE: H for 6 months (negative) HORG trial: H for 6 months (negative) SHORT-HER: H for 3 months (negative) PERSEPHONE: H for 6 months (positive) SOLD: H for 9 weeks (on-going) Adoped from Lambertini M, et al. Expert Rev Cancer Ther 2017.
11 ExteNET: 1 year Neratinib after 1 year of Trastuzumab vs 1 year Trastuzumab alone 5yr DFS absolute benefit = 2.5% Subsets HR idfs Node-negative 0.83 (ns) 1 3+ nodes 0.75 (ns) 4+ nodes 0.67* ER+ 0.60* ER (ns) Positive DFS data persist with longer FU (5-year DFS, Martin M, Lancet Oncol 2017). OS data are still pending! Substantial toxicity (40% G3/4 diarrhea) Diarrhea prophylaxis key! Chan A, et al. Lancet Oncology 2016.
12 APHINITY: 1 year Trastuzumab plus Pertuzumab vs 1 year Trastuzumab plus Placebo Expected: 89.2% 4yr idfs absolute benefit = 1.7% Number needed to treat: 112 Statistically significant, but is it clinically meaningful? von Minckwitz G, et al. N Engl J Med 2017.
13 APHINITY: 1 year Trastuzumab plus Pertuzumab vs 1 year Trastuzumab plus Placebo Node-positive Subgroup Δ 3.2% HR-negative Subgroup Δ 2.3% 2.3% von Minckwitz G et al. N Engl J Med 2017.
14 De-escalating HER2-directed Adjuvant Therapy Trial BCIRG 006 Slamon DJ, et al. SABCS, APT Tolaney SM, et al. N Engl J Med 2015; ASCO 2017, Abstr 511 Study Design No. of patients Treatment Arm DFS Absolute Values HR (95% CI; p) Non-anthracycline- based Cht Phase 3 1,073 AC -> T 10-year DFS: 67.9% 1,074 AC -> TH -> 10-year DFS: Trastuzumab 74.6% for 1 year 0.72 ( ; <0.0001) 1,075 TCH -> 10-year DFS: Trastuzumab 73.0% for 1 year 0.65 ( ; <0.0011) Phase 2 (T1/2 N0) 406 Weekly paclitaxel x 12 + Trastuzumab for 1 year 7-year idfs: 93.3% OS Absolute Values HR (95% CI; p) 10-year OS: 78.7% 10-year OS: 85.9% 0.63 ( ; <0.0001) No significant difference in DFS or OS between Trastuzumab arm; hiowever, trails was not powered to detect equivalence. 10-year OS: 83.3% 0.76 ( ; <0.0075) 7-year OS: 95.0%
15 De-escalating HER2-directed Adjuvant Therapy Trial PHARE Phase 3 Pivot X, et al. Lancet Oncol HORG Phase 3 Mavroudis D, et al. Ann Oncol Short-HER Phase 3 Conte PF, et al., ASCO 2017, Abstr 501. PERSEPHONE Phase 3 Earl H, et al. ASCO 2018, Abstr 506 No. of patients Treatment Arm DFS Absolute Values HR (95% CI; p) OS Absolute Values HR (95% CI; p) Shorter duration of adjuvant Trastuzumab 1690 CT + trastuzumab for 1 year 2-year DFS: 93.8% NR 5.7% Cardiac Events Shorter vs Longer Trastuzumab 1690 CT + trastuzumab for 6 months 2-year DFS: 91.1% 1.28 ( ; 0.29) NR 1.46 ( ; 0.03) 1.9% 241 ddfec -> dddocetaxel + 3-year DFS: 95.7% NR 2 cases trastuzumab for 1 year 240 ddfec -> dddocetaxel + 3-year DFS: 93.3% NR 0 cases trastuzumab for 6 months 1.57 ( ; 0.137) 1.45 ( ; CT + trastuzumab for 1 year 5-year DFS: 87.5.% NR 16% 626 CT + trastuzumab for 9 weeks 5-year DFS: 85.4% NR 6% 1.15 ( ; ns) 2045 CT + trastuzumab for 1 year 4-year DFS: 89.8% NR 12% 2043 CT + trastuzumab for 6 months 4-year DFS: 89.4% 1.07 ( ; 0.01) NR 9%
16 PERSEPHONE and SHORT-HER Subgroups Analysis PERSEPHONE: Subgroups for which 12 m might be superior SHORT-HER: Subgroups for which 6 m might be non-inferior ER- Stage I, II Taxane N0-1 Neoadjuvant Cht Concomitant T Earl H, et al ASCO 2018, Abstr 506; Conte PF, et al. ASCO 2017, Abstr 501. Shorter trastuzumab treatment duration might be equally effective in low stage, ER + disease. However, in all other scenarios 1 year of trastzumab remains the gold standard!
17 Take Home Messages: Adjuvant HER2-directed Therapy 1 year of trastuzumab remains standard in adjuvant therapy of HER2- positive EBC. A dual HER2 blockade with pertuzumab or extended neratinib might be considered in specific populations, higher risk HER2-positive patients, i.e. patients multiple-node positive disease or ER+ disease, respectively. Shorter duration of trastuzumab may be considered in selected, low risk patients who can not tolerate 12 months of therapy. Anthracycline based Cht followed by taxane with concurrent trastuzumab or TCH are proposed regimens. Trastuzumab plus paclitaxel seems to be appropriate therapy patients with T1/2 N0, disease. Additional biomarkers to identify HER2-positive patients suitable for escalation or de-escalation of adjuvant therapy are urgently needed.
18 HER2- directed Therapy for Advanced Breast Cancer (ABC)
19 Cardoso F, et al The Breast 2011.
20 HER2+ Advanced Breast Cancer: Currents Standards of Care in 2018 First line Second line* Later lines**.... Pertuzumab Lapatinib Pertuzumab Lapatinib Trastuzumab Trastuzumab TDM1 Taxane Vinorelbine Capecitabine Superior to trastuzumab + docetaxel (CLEOPATRA) Superior to capecitabine + lapatinib (EMILIA) or to physicians choice (TH3RESA) Superior to lapatinib plus capecitabine (MA.31) Trastuzumab Capecitabine Trastuzumab Superior to lapatinib alone (EGF ) If patients relapse 12 mos start as first line; ** Combination of trstuzumab plus either capecitabine, eribulin, gemciatbine, platinum agents or metronomic Cht might be used as well as per ABC3! Adopted from Piccart M, SABC Symposium 2017; Cardoso F, et al. Ann Oncol 2016.
21 CLEOPATRA: First-line Trastuzumab and Docetaxel +/- Pertuzumab in HER2+ MBC Swain S, et al. NEJM Pertuzumab + trastuzumab+docetaxel Placebo + trastuzumab+docetaxel Hazard ratio P-value ORR % 69.3% PFS months 12.4 months 0.68 < OS months 40.8 months Long term cardiac safety maintained, with favorable LVEF and CHF in experimental arm!
22 EMILIA: T-DM1 vs Lapatinib Plus Capecitabine in HER+ MBC Proportion progression-free Progression-Free Survival by Independent Review Median (months) No. of events Cap + Lap T-DM Stratified HR=0.650 (95% CI, 0.55, 0.77) P< Proportion surviving Overall Survival: Confirmatory Analysis Median (months) No. of events Cap + Lap T-DM Stratified HR=0.682 (95% CI, 0.55, 0.85); P= % Efficacy stopping boundary P= or HR= % 64.7% % Time (months) No. at risk by independent review: Cap + Lap T-DM No. at risk: Time (months) Cap + Lap T-DM Unstratified HR=0.66 (P<0.0001) Data cut-off July 31, 2012; Unstratified HR=0.70 (P=0.0012). T-DM1 Lapatinib + capecitabine Hazard ratio P-value PFS 9.6 months 4.6 months 0.65 <0.001 OS 30.9 months 25.1 months 0.68 <0.001 Verma S, et al. NEJM 2012.
23 HER2+ Advanced Breast Cancer: Standards of Care for Triple Positive Disease in 2018 First line Second line Later lines.... Pertuzumab Lapatinib Lapatinib Trastuzumab Trastuzumab Trastuzumab Trastuzumab Endocrine Therapy TDM1 Endocrine Therapy Vinorelbine Superior to lapatinib alone (EGF ) Superior to trastuzumab + ET (PERTAIN); Induction Cht in 57% Superior to lapatinib or trastuzumab + ET (ALTERNATIVE) Trials comparing HER2 plus ET vs HER2 plus Cht in ABC are ongoing (Detect V, CHEVENDO, PERNETTA, ) Despite absence of EBD, HER2 plus ET might be considered as maintenance therapy as per ABC3. Adopted from Piccart M, SABC Symposium Cardoso F, et al. Ann Oncol 2016.
24 HER2- directed plus ET in First-line Therapy of HR+/HER2+, Triple positive MBC Trial Treatment arm No. pts Median PFS (months) Overall Response Rate (ORR) Overall Survival (months) First-line setting PERTAIN* AI + Trastuzumab % NR Arpino G et al., SABCS /- Pertuzumab** 18.9* 63% Second-line setting ALTERNATIVE AI + Trastuzumab % NR Gradishar WJ et al., ASCO 2017, Abstr AI + Lapatinib AI + Trastuzumab + Lapatinib * 19% 32%* * PERTAIN: Induction Cht in 57%. Dual HER2 blockade plus ET performs better than mono HER2 plus ET; however; therefore, it is a reasonable option in selected HR+/HER2+ patients, used as induction or as maintenance therapy. Gradishar WJ, et al. ASCO 2017, Abstr 1004.
25 Treatment of CNS Metastases in HER2+ MBC
26 Trastuzumab Improves Survival in Patients with CNS Disease: Retrospective Analysis Kirsch DG, et al. JCO 2005
27 CEREBEL: Capecitabine plus Lapatinib or Trastuzumab in HER2+ MBC without CNS mets Early closure! Lapatinib + capecitabine (N=251) Trastuzumab + capecitabine (N=250) OS (ITT population) OR (95% CI) P-value CNS at first site of relapse, n (%) 8 (3) 12 (5) 0.65 ( ) Incidence of CNS progression at any time, n (%) 17 (7) 15 (6) 1.14 ( ) Time to first CNS progression, median (range) 5.7 (2-27) 4.4 (2-27) - - Low number of brain metastses Trastuzumab + capecitabine better OS Survival (%) Lap + Cap (N=271) Tras + Cap (N=269) Median OS, months Hazard ratio (95% CI) 1.34 (0.95,1.90) Stratifiedlog-rank p-value Pivot X, et al. J Clin Oncol Subjects at risk Lap + Cap Tras + Cap Time from randomisation (months)
28 Efficacy of Pertuzumab + Trastuzumab and of T-DM1 in CNS metastases Post-hoc Analyses of CLEOPATRA, EMILIA Median time to progression, CNS as first site of progression Progression-free probability (%) Pertuzumab, trastuzumab, docetaxel Trastuzumab, docetaxel, placebo HR % CI 0.39, 0.85 p = Time (months) 45 No. PHTat risk HT Patients without prior chemotherapy or biologic therapy for HER2-positive MBC were included; patients with evidence of CNS metastases were excluded Swain S, et al. Ann Oncol Krop I, et al. Ann Oncol 2015.
29 Novel Treatment Strategies for HER2+ Breast Cancer in Clinical Research New HER2-directed Agents New anti-her TKIs (tucatinib, poziotinib) Antibody Drug Conjugates (ADCs) New anti-her Antibodies Bi-specific Antibodies New Combinations Anti-HER2 + mtor Inhibitors Anti-HER2 + PI3K Inhibitors Anti-HER2 + CDK 4/6 Inhibitors Anti-HER2 + PD-1/PD-L1 Inhibitors New predictive markers for better tailoring of HER2-directed therapy are urgently needed! So far, we only have additional prognostic markers (HER2 mrna, PIK3CA, TIL), while HER2 status remains the only predictive biomarker, after decades of research in HER2+ breast cancer! At least we should take into consideration that triple positive breast cancer is a distinctive subtype!
30 Take Home Messages: HER2-directed Therapy of ABC Trastuzumab plus pertuzumab plus taxane represents the standard firstline therapy for ABC pts, not receiving previous HER2-directed therapy. When pertuzumab is not given (available) trastuzumab plus taxane or vinorelbine should be given in first-line setting! T-DM1 represents the standard second-line therapy in ABC pts receiving previous HER2-directed therapy. T-DM1 can be considered as alternative to trastuzumab/taxane combination in the first-line setting, mainly for patients with short DFI (< 12 mos) after neo-/adjuvant HER2-directed therapy. For later lines of therapy trastuzumab plus Cht, lapatinib plus capecitabine or trastuzumab plus lapatinib remain viable options.
31 Take Home Messages: HER2-directed Therapy of ABC For selected triple positive, especially elderly patients with a low burden of disease, a combination of ET and dual HER2-directed therapy with trastuzumab plus pertuzumab in first-line or with trastuzumab plus lapatinib in second-line can be considered, as upfront or as maintenance therapy. Optimal duration of HER2-directed therapy in ABC patients achieving CR is not yet known. Stopping HER-2 therapy might considered if re-challenge is available in case of progression. Patients with CNS disease benefit from HER2-directed therapy: trastuzumab plus capecitabine, trastuzumab plus pertuzumab plus taxane or T-DM1 are viable options. Intrathecal trastuzumab might be considered in patients with leptomeningeal disease (Zagouri, et al. BCRT 2013.).
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationTreatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More information(Neo) Adjuvant systemic therapy for HER-2+ EBC
(Neo) Adjuvant systemic therapy for HER-2+ EBC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
More informationCurrent and Future perspectives of HER2+ BC
2018.4.6 GBCC Satellite symposium Current and Future perspectives of HER2+ BC Jee Hyun Kim, M.D., Ph.D. Seoul National University Bundang Hospital Seoul National University College of Medicine Disclaimer
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More information(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC
(NEO-)ADJUVANT THERAPY FOR HER-2+ EBC Rebecca Dent, MD FRCP (Canada) Senior Consultant, National Cancer Center Singapore Associate Professor, Duke-NUS www.abc-lisbon.org When to question a pathology report?
More informationEnfermedad con sobreexpresión de HER-2 neu
Enfermedad con sobreexpresión de HER-2 neu Elsa Dalmau Parc Taulí Sabadell. Hospital Universitari. Enfermedad con sobreexpresión de HER-2 neu ÍNDICE Neoadyuvancia Adyuvancia Enfermedad avanzada Enfermedad
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationNew Drug Development in HER2+ Breast Cancer
New Drug Development in HER2+ Breast Cancer Philippe Aftimos, M.D. Senior Research Physician Clinical Pharmacology Unit Institut Jules Bordet Background Amplification of HER2 occurs in approximately 20%
More informationUpdate HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationTarget biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica
Target biologico e meccanismo d azione dei farmaci anti-her2: il continuum dal setting Neoadiuvante alla malattia metastatica Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More information2
1 2 Systematic review of published evidence PUBMED 1999-2017 ASCO 1999-2017 SABCS 1999-2017 ECCO/ESMO 1999-2017 3 Statement: Anthracycline/ taxane based chemotherapy 1. Budd GT et al. SWOG S0221: A Phase
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationHer 2 Positive Metastatic Breast Cancer
Her 2 Positive Metastatic Breast Cancer Alison Jones November 2013 Mrs Hermione Positive (then and now!) Diagnosed 2007 T2 N1 Mo ER ve; Her2 ve Mastectomy ANC; FEC/T Herceptin (12months) August 2010metastatic
More informationTreatment of Early Stage HER2-positive Breast Cancer
Treatment of Early Stage HER2-positive Breast Cancer 3 November 2012 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky Lexington, KY Molecular Portrait
More informationBiomarker research in HER2 positive breast cancer : a journey into the desert
WIN 9th Symposium 2017 Expediting Global Innovation in Precision Cancer Medicine Paris, June 26 & 27, 2017 Biomarker research in HER2 positive breast cancer : a journey into the desert Martine J. Piccart-Gebhart,
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationShould pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Commentary Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results? Tom Wei-Wu Chen 1, Ching-Hung Lin 1,2, Chiun-Sheng Huang 3 1 Department of Oncology,
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationIl trattamento medico
III Sessione: La malattia in fase avanzata Il trattamento medico Emilio Bria Oncologia, Dipartimento di Medicina, Università di Verona, Azienda Ospedaliera Universitaria Integrata Verona emilio.bria@univr.it
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationASCO 2018 Breast Cancer updates. June 29 th 2018 Einav Gal-Yam Sheba MC
ASCO 2018 Breast Cancer updates June 29 th 2018 Einav Gal-Yam Sheba MC Early BC Adjuvant Chemotherapy benefit in HR-pos Nneg BC TAILORX Slide 1 Presented By Joseph Sparano at 2018 ASCO Annual Meeting TAILORx
More informationBreast Cancer: Chemotherapy and Novel Agents
North Carolina Oncology Association & South Carolina Oncology Society Joint Membership Meeting ~ February 26 27, 2010 The Ballantyne Resort ~ Charlotte, NC Breast Cancer: Chemotherapy and Novel Agents
More informationUpdates in HER2-Targeted Therapy from SABCS Outline
Updates in HER2-Targeted Therapy from SABCS 2018 Melanie Majure, MD Assistant Professor University of California San Francisco Helen Diller Comprehensive Cancer Center Outline Neoadjuvant Therapy (PEONY;
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationBREAST CANCER RISK REDUCTION (PREVENTION)
BREAST CANCER RISK REDUCTION (PREVENTION) Articles Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled
More informationSessione 4: La malattia metastatica. La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G.
Sessione 4: La malattia metastatica La malattia HER2-positiva: strategia terapeutica nella pratica clinica e il futuro G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo giusyricciardi81@hotmail.it
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More information2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01
More informationPIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
More informationSYSTEMIC THERAPY FOR HER-2+ ABC
SYSTEMIC THERAPY FOR HER-2+ ABC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationAdvances in the Management of Metastatic Her 2 Positive Breast Cancer
Advances in the Management of Metastatic Her 2 Positive Breast Cancer Sunil Verma MD, MSEd, FRCPC Medical Oncologist Research Lead, Division of Medical Oncology Chair, Breast Medical Oncology Sunnybrook
More informationCerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara
Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara CNS metastases in HER2+ BC The proportion of patients with HER2+ advanced breast cancer who have CNS metastases
More informationWhat is the Next Goal for HER2 Targeted Therapy?
What is the Next Goal for HER2 Targeted Therapy? Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education University of California San Francisco Helen Diller Family Comprehensive Cancer
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationDEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO
DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO CÁNCER DE MAMA HER 2 POSITIVO DEBATE: NUEVOS TRATAMIENTOS EN CÁNCER DE MAMA POSICIONAMIENTO Y ALGORITMO TERAPÉUTICO
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationDo we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD
Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer
More informationIntroduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationSession Breast Cancer. Alessandra Fabi Il punto di vista dell esperto
Session Breast Cancer Alessandra Fabi Il punto di vista dell esperto Roma 6-7.10.2017 The Importance of Understanding What Disease to Treat Cejalvo et al, Cancer Res 2017 Skyline Chaging at evolution of
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationAnthracyclines in the elderly breast cancer patients
Anthracyclines in the elderly breast cancer patients Etienne GC Brain, MD PhD Medical Oncology Centre René Huguenin, Saint-Cloud & Group GERICO, FNCLCC, Paris Centre René Huguenin - Saint-Cloud Facts about
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More information